Objective: To examine the effect of an albumin-binding prodrug of methotrexate (MTX) in the treatment of murine collagen-induced arthritis (CIA).
Methods: The prodrug AWO54 with the formula EMC-D-Ala-Phe-Lys-Lys-MTX binds selectively to the cysteine-34 position of endogenous albumin, which acts as a macromolecular drug carrier for MTX to the site of inflammation. The CIA model was used to evaluate the anti-arthritic effect of the compound after intravenous application.
Results: The albumin-bound form of AWO54 was efficiently cleaved by cathepsin B and plasmin, two proteases that are over-expressed in rheumatoid arthritis, and release a MTX lysine derivative. AWO54 suppressed collagen-induced arthritis in a dose-dependent manner and was significantly superior to MTX. To obtain a similar effect only about 20% of the MTX-equivalent dose of AWO54 had to be given in comparison to MTX. The efficacy of the drug was tested in two different stages of CIA: While both, MTX and AWO54 inhibited arthritis in an early stage of the disease, in a later stage only AWO54 showed a significant inhibitory effect in comparison to control.
Conclusion: Targeted drug delivery by in vivo coupling of a prodrug of MTX to endogenous albumin is superior to MTX in the treatment of CIA.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.